MA-WOLTERS-KLUWER-HEALTH
17.11.2022 20:01:35 CET | Business Wire | Press release
Wolters Kluwer Health and NEJM Group have entered into an exclusive partnership to ensure that more researchers and clinicians around the world can access the growing family of NEJM Group journals. Building on years of collaboration, this expanded partnership positions NEJM Group journals for sustained global growth through Wolters Kluwer’s Ovid® medical research platform. Publications currently included are the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst Innovations in Care Delivery, NEJM Journal Watch, the NEJM Archive, and future NEJM Group journals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005838/en/
Wolters Kluwer Health will serve as the exclusive digital distributor of subscriptions to the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst and NEJM Journal Watch (Graphic: Business Wire)
Unparalleled distribution critical to global reach
“The mission of NEJM Group is to advance medical knowledge from research to patient care, making the connections between developments in clinical science and clinical practice to improve healthcare quality and patient outcomes worldwide,” said David Sampson, Vice President of NEJM Group. “Wolters Kluwer’s worldwide sales and marketing presence creates additional opportunities to expand the reach of our content by delivering the NEJM Group portfolio of products to institutions globally.”
Through the partnership, institutional online subscribers to NEJM Group journals will be able to access their subscriber content both on NEJM Group sites and on the Ovid® medical research platform. Spanning over 150 publishers and more than 100 specialty areas, Ovid serves as the powerful, one-stop research software to help researchers, librarians, clinicians, and other healthcare professionals find timely and relevant medical information to make critical decisions to improve patient care, enhance ongoing research, and fuel new discoveries. With the addition of NEJM Group titles, Ovid users will be able to search and access the best research and information at the intersection of biomedical science and clinical practice, supporting improved patient care and clinical outcomes.
“The New England Journal of Medicine is one of the most highly respected and impactful medical periodicals in the world, drawing on a rich history, and cited more than any other journal,” said Vikram Savkar, Senior Vice President & General Manager, Medicine Segment, Health Learning, Research & Practice at Wolters Kluwer. “Leveraging Ovid’s market-leading search technology alongside Wolters Kluwer’s global sales and marketing reach will ensure more access to NEJM Group journals and archives around the world. Bringing together NEJM Group and Wolters Kluwer creates a global research powerhouse for clinicians seeking answers to care questions and researchers pursuing the next great discovery.”
The partnership builds on a strong foundation that has been fortified over many years of collaboration and a shared vision for the future of healthcare. Both NEJM Group and Wolters Kluwer maintain the highest standards for curation and peer review, and both support increased access to data and research globally. NEJM Group content around matters of public health importance, such as Covid-19, will continue to be available for free.
NEJM Group publications that will be distributed to institutions via Wolters Kluwer include:
- The New England Journal of Medicine, recognized as the world’s leading medical journal, delivering high-quality, peer-reviewed research and interactive clinical content to physicians, educators, researchers, and the global medical community.
- NEJM Evidence, which presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
- NEJM Catalyst Innovations in Care Delivery, a peer-reviewed journal focusing on the latest innovations, big ideas, and practical solutions for healthcare delivery transformation.
- NEJM Journal Watch, which helps clinicians efficiently understand medical developments to improve patient care and foster professional development.
As a result of this distribution agreement, Wolters Kluwer Health Learning, Research & Practice will account for NEJM Group digital subscription revenues and related costs. The agreement has a positive but immaterial impact on the consolidated earnings of the Wolters Kluwer group.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer Health provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom